Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
News about Collegium Pharmaceutical, Inc. (Nasdaq: COLL) focuses on its activities as a biopharmaceutical company with a portfolio spanning responsible pain management and neuropsychiatry. The company regularly issues press releases on product-related research, financial performance, capital structure, and corporate initiatives, providing investors and healthcare professionals with insight into its operations.
A major theme in Collegium’s news flow is the development and commercialization of JORNAY PM, a central nervous system stimulant indicated for the treatment of ADHD in people 6 years of age and older. The company highlights real-world data on JORNAY PM at scientific meetings such as the American Professional Society of ADHD and Related Disorders (APSARD), the American Academy of Child & Adolescent Psychiatry, and the Neuroscience Education Institute conferences. Releases describe poster presentations on dosing, comparative outcomes versus other ADHD treatments, and changes in functioning and psychiatric symptoms in various patient groups.
Collegium also issues news on its pain portfolio, including BELBUCA and XTAMPZA ER. At events like PAINWeek, the company presents multiple posters that examine treatment characteristics, safety, economic burden, and clinical outcomes for patients with chronic pain. These communications underscore Collegium’s focus on responsible pain management and real-world evidence generation.
Investors following COLL can find regular updates on quarterly financial results, guidance, and non-GAAP metrics such as adjusted EBITDA in the company’s earnings press releases. Additional news covers capital deployment, including share repurchase authorizations and the closing of a syndicated credit facility, as well as participation in healthcare and investor conferences. For those tracking developments in ADHD treatment and opioid-based pain therapies, the Collegium news page offers an organized view of clinical data, commercial progress, and financial disclosures over time.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) will announce its Q2 2022 financial results on August 4, 2022, after market closure. A corresponding conference call will be held at 4:30 p.m. ET, allowing investors to discuss the financial outcomes live. To participate, dial (877) 407-8037 for U.S. callers or (201) 689-8037 internationally, referencing the 'Collegium Pharmaceutical Q2 2022 Earnings Call.' An audio webcast will also be available on the company's website, with a replay accessible two hours post-event.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation at the H.C. Wainwright Global Investment Conference, scheduled for May 23-26, 2022, at the Fontainebleau Miami Beach Hotel. Collegium’s presentation is set for May 24, 2022, at 3:30 pm ET. The company is focused on improving the lives of those with serious medical conditions and is headquartered in Stoughton, Massachusetts. For more information, visit www.collegiumpharma.com.
Collegium Pharmaceuticals reported Q1 2022 net revenue of $83.8 million, down from $87.7 million in Q1 2021. The BDSI acquisition is on track to exceed targeted run rate synergies of $75 million. The company has resolved all opioid-related litigation and provided financial guidance for 2022, expecting revenues between $450 million and $465 million. Despite a net loss of $13.1 million this quarter, Collegium’s outlook remains positive with a cash balance of $106.7 million.
Collegium Pharmaceutical (Nasdaq: COLL) will host a conference call on May 10, 2022, at 4:30 p.m. ET, to discuss its Q1 2022 financial results and provide a corporate update. Interested parties can join by dialing (877) 407-8037 for U.S. callers or (201) 689-8037 for international callers. The call will also be available via a live audio webcast on the company’s website, with replays accessible two hours after the event.
Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical (Nasdaq: COLL) announced its participation in the 21st Annual Needham Virtual Healthcare Conference, set for April 13, 2022. Management will engage in a virtual fireside chat, which will be webcast and accessible through the investor section of the company's website. A replay will be available for 30 days following the event. Collegium is dedicated to enhancing the lives of those with serious medical conditions, headquartered in Stoughton, Massachusetts. For more details, visit www.collegiumpharma.com.
Collegium Pharmaceutical (Nasdaq: COLL) announced the appointment of Neil F. McFarlane to its Board of Directors, effective April 6, 2022. McFarlane brings extensive experience from previous leadership roles at Adamas Pharmaceuticals and Retrophin. The Chairman, Mike Heffernan, expressed confidence in McFarlane's ability to provide valuable insights and contributions. This strategic addition comes as the company aims to enhance its operations and improve the lives of individuals with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has updated its financial guidance for 2022 following the acquisition of BioDelivery Sciences International on March 22, 2022. Expected total product revenues are projected between $450.0 million and $465.0 million, reflecting a 65% increase from $276.9 million in 2021. Adjusted operating expenses are estimated at $130.0 million to $140.0 million and adjusted EBITDA is expected to reach $235.0 million to $250.0 million. The company aims for operational synergies of at least $75 million as it integrates BDSI.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has reached a Master Settlement Agreement to resolve 27 opioid-related lawsuits without admitting liability. Executed on March 18, 2022, the company has paid $2.75 million to the plaintiffs, leading to case dismissals anticipated in the upcoming weeks. This settlement follows a previously announced framework from December 2021, marking a strategic decision to mitigate legal risks. Collegium aims to strengthen its position as a specialty pharmaceutical company focused on aiding patients with serious medical conditions.
Collegium Pharmaceutical (Nasdaq: COLL) has completed its acquisition of BioDelivery Sciences International (Nasdaq: BDSI) for $5.60 per share, totaling approximately $40 million. This strategic move aims to enhance Collegium's revenue through diversification, adding products like BELBUCA and ELYXYB to its portfolio. The acquisition is expected to yield annual synergies of at least $75 million within the first year, strengthening Collegium's financial position and accelerating cash flow generation, while expanding its footprint in the neurology market.
Collegium Pharmaceutical (Nasdaq: COLL) reported its Q4 and full-year 2021 financial results, revealing a net loss of $25 million for Q4 and $71.5 million net income for the full year. The company anticipates 2022 revenues between $315 million and $330 million, driven by growth in Xtampza ER. They expect the BDSI acquisition to close in late Q1 2022, aiming for synergies exceeding $75 million. Despite challenges, Collegium ended 2021 with a cash balance of $186.4 million and achieved significant market share gains in Xtampza ER, with a 33% share of the oxycodone extended-release market.